Notably, some data from literature show that higher levels of syndecan-1 were correlated with the symptomatology and severity of heart failure, an elevation of the serum biomarker being more commonly met in patients with NYHA III/IV functional class, compared to those in NYHA I/II [44, 45]. Here, SDC1 is linked to heart failure.